Therapeutic targets for cardiac fibrosis: from old school to next-gen

Area of Science:

• Cardiovascular Medicine
• Fibrosis Research
• Epigenetics

Background:

• Cardiovascular diseases are the leading global cause of death.
• Pathological cardiac fibrosis, mediated by myofibroblasts, underlies cardiac dysfunction and heart failure.
• Current treatments targeting cardiac fibroblasts and fibrosis are limited.

Purpose of the Study:

• To review classical regulators of cardiac fibrosis.
• To highlight emerging epigenetic targets for therapeutic intervention.
• To explore novel strategies for mitigating myofibroblast activation and cardiac fibrosis.

Main Methods:

• Literature review of classical fibrosis regulators.
• Analysis of emerging epigenetic mechanisms in cardiac fibrosis.
• Discussion of therapeutic potential for cardiovascular diseases.

Main Results:

• Myofibroblast activation is a key factor in fibrotic remodeling.
• Epigenetic modifications represent promising targets for antifibrotic therapies.
• Targeting fibrosis could treat diverse heart conditions.

Conclusions:

• Novel epigenetic strategies hold potential to revolutionize cardiovascular disease treatment.
• Mitigating cardiac fibrosis offers a promising therapeutic avenue for heart failure and related conditions.
• Further research into epigenetic regulators is crucial for developing effective antifibrotic therapies.